AbbVie Inc.
ABBV · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -6.80 | -3.30 | -0.02 | 35.00 |
| FCF Yield | 1.83% | 1.48% | 0.38% | 2.15% |
| EV / EBITDA | 137.46 | 90.45 | 98.90 | 704.05 |
| Quality | ||||
| ROIC | 1.28% | 3.38% | 2.76% | -0.01% |
| Gross Margin | 78.51% | 84.42% | 70.01% | 70.89% |
| Cash Conversion Ratio | 37.36 | 5.48 | 1.27 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.65% | 1.35% | 0.37% | -1.00% |
| Free Cash Flow Growth | 54.14% | 248.86% | -79.28% | 29.99% |
| Safety | ||||
| Net Debt / EBITDA | 18.33 | 14.74 | 14.71 | 116.48 |
| Interest Coverage | 7.33 | 7.92 | 5.33 | -2.12 |
| Efficiency | ||||
| Inventory Turnover | 0.69 | 0.48 | 0.88 | 1.05 |
| Cash Conversion Cycle | -681.77 | -932.70 | -510.29 | -502.63 |